Setting up out-of-hours GP services next to accident and emergency departments could help stem the flow of patients seeking urgent care in hospitals.
News
EU approves constipation drugs
Men suffering from constipation in Europe can now get treatment with Shire’s Resolor after regulators issued another green light substantially expanding its reach.
Safety of Sprout’s ‘female viagra’ in the spotlight again
Sprout’s female sexual desire pill is in the spotlight again as US regulatory advisors gear up to assess whether its benefit outweighs its risks.
Merck, Dynavax link up to test cancer immunotherapy regimens
Another day, another onco-immunology tie-up, and this time it’s Merck & Co and Dynavax unveiling a new collaboration to investigate combinations of their investigational drugs.
NICE U-turn on Boehringer’s Vargatef for lung cancer
Certain patients with lung cancer could soon get routine access to Boehringer Ingelheim’s Vargatef on the National Health Service after a u-turn by cost regulators.
Perrigo snaps up OTC brands from GSK
Irish drugmaker Perrigo has unveiled its intention to buy a batch of over-the-counter brands from GlaxoSmithKline.
Roche’s Gazyvaro, Bayer’s Eylea backed for NHS use
Cost regulators for the National Health Service in England and Wales have endorsed funding for Roche’s cancer therapy Gazyvaro, Bayer’s eye jab Eylea and Allergan’s eye implant Ozurdex.
Roche signs cancer trial pact with Amgen
Roche and Amgen will work together on a Phase Ib study looking at the safety and efficacy of combining their respective immunotherapies atezolizumab and T-VEC in patients with triple-negative breast cancer and colorectal cancer with liver metastases.
BMS drug pair cut melanoma progression, but Opdivo disappoints in lung cancer
Bristol-Myers Squibb’s checkpoint inhibitors Opdivo and Yervoy are together more powerful against melanoma than the latter alone, according to Phase III data presented at the American Society of Clinical Oncology conference in Chicago.
EU OKs Eisai’s thyroid cancer drug Lenvima
European regulators have issued clearance for Eisai’s Lenvima to treat the most common forms of thyroid cancer, following approvals in the US and Japan earlier this year.
FDA priority review for Opdivo/Yervoy combo in skin cancer
US regulators have agreed to review a supplemental filing for Bristol-Myers Squibb’s combination of immunotherapies Opdivo and Yervoy in patients with previously untreated advanced melanoma.
NICE says AZ’ ovarian cancer drug is too expensive
Preliminary guidelines from the National Institute for Health and Care Excellence have rejected the use of AstraZeneca’s ovarian cancer drug Lynparza by the National Health Service in England and Wales because it is too expensive, sparking dismay among cancer charities.
Pfizer’s Rapamune wins US nod for rare lung disease
US regulators have waved a green flag for the use of Pfizer’s Rapamune to treat the ultra-rare, progressive and often fatal lung disease lymphangioleiomyomatosis (LAM).
Lilly, AZ to test solid tumours combo
AstraZeneca and Eli Lilly will test the potential of combining their immunotherapy and angiogenesis-inhibiting cancer drugs to treat patients with advanced solid tumours.
Merck, Amgen to test combo in head and neck cancer
Merck & Co and Amgen are expanding their existing collaboration to test a combination of their respective immunotherapies Keytruda and T-VEC in patients with head and neck cancer.
